Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Beer-only drinkers’ diets are worse than wine drinkers

Written by | 24 Nov 2024

Beer drinkers have lower-quality diets, are less active, and are more likely to smoke cigarettes than people who drink wine, liquor, or a combination, according to a study… read more.

Aligos Therapeutics announces positive data on chronic hepatitis B and MASH treatments at AASLD 2024

Written by | 22 Nov 2024

Aligos Therapeutics, Inc. a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from… read more.

Late breaking data for Iqirvo (elafibranor) from interim analysis of Phase III ELATIVE study for Primary Biliary Cholangitis at AASLD meeting – Ipsen

Written by | 20 Nov 2024

Ipsen announced  late-breaking data for Iqirvo (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American… read more.

GSK showcases advances in chronic Hepatitis B and Cholestatic Pruritus research at AASLD liver meeting 2024

Written by | 16 Nov 2024

GSK plc (will present 12 abstracts at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2024, taking place in San Diego, CA from 15-19… read more.

AASLD 2024: Mirum presents breakthrough data on Maralixibat and Volixibat for cholestatic liver diseases

Written by | 15 Nov 2024

Mirum Pharmaceuticals, Inc. (announced that it will present data at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting®, taking place November 15-19, 2024,… read more.

2024 AASLD Liver Meeting to feature Madrigal Pharmaceuticals’ new Insights on Resmetirom for NASH

Written by | 2 Nov 2024

Madrigal Pharmaceuticals, Inc. a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH),  announced multiple resmetirom data presentations at the upcoming American Association… read more.

DURECT Corporation to highlight new data on Larsucosterol for alcohol-associated hepatitis at The Liver Meeting 2024

Written by | 21 Oct 2024

DURECT Corporation a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce… read more.

For heavy drinkers, chronic pain associated with alcohol withdrawal could be permanent

Written by | 20 Oct 2024

One of the main physical symptoms of alcohol withdrawal is “allodynia”— increased sensitivity to mechanical stimuli that are normally innocuous, which is a clinical sign of chronic pain…. read more.

Imfinzi (durvalumab) + Imjudo (tremelimumab) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA phase III trial – AstraZeneca

Written by | 22 Sep 2024

Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at five years for… read more.

Livdelzi (seladelpar) granted accelerated approval for primary biliary cholangitis by FDA – Gilead Sciences

Written by | 13 Sep 2024

Gilead Sciences, Inc. announced that the FDA has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA)… read more.

Could a novel liver patch help treat and prevent liver disease?

Written by | 25 Jun 2024

As described in research published in the Biotechnology Journal, investigators have developed a novel patch that can help liver tissue regenerate. The patch is a combination of decellularized liver… read more.

Opdivo + Yervoy significantly improved overall survival compared to lenvatinib or sorafenib as first-line treatment for patients with advanced hepatocellular carcinoma in CheckMate -9DW trial – BMS

Written by | 10 Jun 2024

Bristol Myers Squibb announced the first presentation of results from the Phase III CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.